ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International…
By K. Savage, N. Harris, J. Vose, F. Ullrich, Elaine S. Jaffe, J. Connors, L. Rimsza, S. Pileri, M. Chhanabhai, R. Gascoyne and 2 more. Blood, 2008
768 citations recorded by the source corpus.
Subfields: Dermatology, Immunology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/28ed6de13d3750d7c31ae6cf4aebf9afe8601ecb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pathology and Forensic Medicine
Citations in the corpus
- Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. (2012, background): “© 2012 by American Society of Clinical Oncology INTRODUCTION Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell lymphoma representing approximately 2% to 3% of all lymphoid neoplasms.1,2 On the basis of the expression of the anaplastic lymphoma kinase (ALK) protein, AL”
- Automatic lymphoma classification with sentence subgraph mining from pathology reports. (2014, background): “Since its original publication, several case series and reviews of lymphoma have suggested refinements to the current classification scheme and additional lymphoma subtypes [9][10][11][12][13].”
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. (2011, result): “ALK-positive ALCL occurs mainly in pediatric and young age groups, has a better prognosis than ALK-negative ALCL, and exhibits differences in genetics and GEP.58-60 The categorization of ALK-negative ALCL was more controversial but also felt to be distinguishable from other PTCLs. Recent studies by ”
- Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. (2009, unknown): “Bangkok, Thailand 41 14 (34) 7 (17) 21 (51) Hong Kong, China 58 12 (21) 5 (9) 3 (5) 20 (34) Singapore 34 9 (27) 8 (24) 2 (6) 19 (56) Seoul, Korea 27 5 (19) 6 (22) 11 (41) Tokyo, Japan 32 4 (13) 4 (13) Nagoya, Japan 54 9 ( 17 ) 1 (2) 10 (19) Okayama, Japan 36 7 (20) 7 (19) Fukuoka, Japan 182 11 (6) 1”
- The 2008 WHO classification of lymphomas: implications for clinical practice and translational research (2009, unknown): “Recent clinical studies appear to support this resolution, as the former has a better prognosis and evidence of a plateau, at least in a proportion of patients.(71) Stringent morphologic and immunophenotypic criteria are required for the diagnosis of ALK ALCL as CD30 may be expressed in a variety of”